<DOC>
	<DOCNO>NCT00396110</DOCNO>
	<brief_summary>In study effect switch rosuvastatin another statin ( fluvastatin , pravastatin , simvastatin , atorvastatin ) evaluate high-risk patient without evident CHD LDL-C â‰¥ 3.2 mmol/l . This do large observational study ( TARGET ) represent daily practice . Primary end point analysis percentage patient reach target LDL-C &lt; 3.2 mmol/l . Secondary outcome change LDL-C , HDL-C , TC , Triglycerides ( TG ) TC/HDL-C-ratio baseline .</brief_summary>
	<brief_title>Evaluation Efficacy Rosuvastatin Daily Practice ( TARGET )</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Highrisk patient without evident CHD LDLC &gt; 3.2 mmol/l treat moment HMGCoAreductase inhibitor apart rosuvastatin . Patients age &gt; 18 year &lt; 70 year ( men ) &lt; 75 year ( woman ) . Treatment atorvastatin 40 80 mg simvastatin 80 mg Patients familiar muscular pain , myopathy liver function disorder ( inclusive elevation serum transaminase ) and/or contraindication treatment rosuvastatin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2003</verification_date>
	<keyword>cholesterol</keyword>
	<keyword>coronary heart disease</keyword>
	<keyword>rosuvastatin</keyword>
	<keyword>LDL-C goal</keyword>
	<keyword>hypercholesterolemia</keyword>
</DOC>